Looking for research-grade compounds?
Thymosin alpha-1 peptide research occupies unusual ground in the peptide world. Most research peptides have cell data, animal data, and not much else. Thymosin alpha-1 (Tα1) has all of that plus something rare: decades of human clinical trials, a licensed pharmaceutical version sold in dozens of countries, a Phase 3 sepsis trial of more than 1,100 patients published in The BMJ in 2025 — and still no FDA approval in the United States. That combination makes it one of the best case studies in the field for a hard lesson: a peptide can be biologically active, extensively studied, and generally well tolerated, and the largest, best-controlled trials can still fail to show the benefit smaller studies suggested. This article covers what thymosin alpha-1 is, how it signals through dendritic cells, what the trial record actually shows indication by indication, and why its US regulatory status looks the way it does. Everything here is framed strictly for laboratory research.
Thymosin alpha-1 is a 28-amino-acid peptide originally isolated in the 1970s from thymosin fraction 5, a preparation of calf thymus tissue studied by Allan Goldstein’s group. In the body, the same sequence is produced by cleavage of a larger precursor protein, prothymosin alpha. The synthetic version — international nonproprietary name thymalfasin, brand name Zadaxin — is chemically identical to the natural peptide, including its acetylated N-terminus, and is manufactured by solid-phase peptide synthesis.
| Property | Thymosin alpha-1 |
|---|---|
| Sequence | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn |
| One-letter code | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN |
| Length | 28 amino acids |
| Molecular formula | C129H215N33O55 |
| Molecular weight | ~3,108.3 g/mol |
| PubChem | CID 16130571 (thymalfasin) |
| CAS | 62304-98-7 |
| N-terminal modification | Acetylation — essential to its activity and stability |
| Disulfide bonds | None — the sequence contains no cysteine |
| Pharmaceutical form | Thymalfasin (Zadaxin), approved in 30+ countries, not in the US or EU |
| FDA approval | None, for any indication |
| Reported plasma half-life | ~2 hours in human pharmacokinetic studies of thymalfasin |
For background on peptide structure and terminology, see our overview of what peptides are and the Apex peptides library.
The thymus is where T cells mature, and thymic extracts were studied for decades for factors that could direct that maturation. Thymosin fraction 5 contained a mixture of small peptides; fractionation isolated thymosin alpha-1 as one of its most active components in immune assays. Two structural features explain much of its research appeal. First, the N-terminal acetyl group shields the peptide from aminopeptidases that would otherwise clip it from the free end, and it is required for the immunoregulatory activity that distinguishes Tα1 from its precursor. Second, the chain is rich in charged and polar residues — glutamate, lysine, aspartate, serine — which makes it highly water-soluble and shapes how it interacts with cell-surface and endosomal receptor systems. Researchers shopping for research material (the “peps” and “ruo” end of the market) should note that a sequence listing without the “Ac-” prefix is not describing the same molecule.
The most important sentence in the thymosin alpha-1 literature is that it is a modulator, not a straightforward immune stimulant. Its best-characterized target cell is the dendritic cell — the antigen-presenting cell that decides what kind of immune response follows an encounter — and its effects run in two directions at once.
Work by Romani, Bistoni, Puccetti and colleagues showed that Tα1 primes dendritic cells for antifungal T-helper type 1 (Th1) resistance through Toll-like receptor 9 (TLR9) and its MyD88 adaptor pathway. In plasmacytoid dendritic cells, TLR9/MyD88 signaling engages interferon regulatory factor 7 (IRF7), promoting type I interferon responses; in the group’s animal models this translated into protection against invasive aspergillosis and primary murine cytomegalovirus infection. Downstream readouts reported across the literature include increased expression of MHC class I, maturation of dendritic cells, and Th1-type cytokine patterns such as interferon-gamma and interleukin-2, together with effects on natural killer cells and T-cell differentiation.
The same research program found the counterweight. In a widely cited 2006 study in Blood, Romani and colleagues showed that Tα1 also induces indoleamine 2,3-dioxygenase (IDO) in dendritic cells, in a process requiring TLR9 and type I interferon receptor signaling. IDO is the rate-limiting enzyme of tryptophan catabolism; its activation produces interleukin-10 and supports regulatory T-cell generation — a tolerogenic program. TLR2 engagement on myeloid cells has likewise been linked to MyD88/NF-κB signaling with IL-10 and IDO expression. Complementary work in human monocyte-derived dendritic cells found rapid activation of p38 MAPK and NF-κB (via IκBα phosphorylation) within minutes of exposure.
Put together, Tα1 appears to push dendritic cells toward effector immunity and toward tolerance at the same time, with the surrounding inflammatory context influencing which program dominates. That duality is the honest mechanistic summary — and it predicts exactly the clinical pattern that followed: real biological activity, with benefits that prove hard to pin to a single indication.
Thymosin alpha-1 is routinely confused with thymosin beta-4 and its fragment TB-500. They share a name and a tissue of origin, and almost nothing else:
| Thymosin alpha-1 | Thymosin beta-4 / TB-500 | |
|---|---|---|
| Family | Alpha thymosins | Beta thymosins |
| Length | 28 amino acids | 43 amino acids (TB-500 is a 7-aa fragment of it) |
| Core biology | Dendritic-cell and T-cell immunomodulation via TLR pathways | Actin sequestration, cell migration, tissue-repair models |
| Human trial history | Extensive — Phase 2/3 trials across hepatitis, sepsis, oncology adjuncts | Full-length Tβ4 trialed (eye, skin, cardiac); the TB-500 fragment itself has no human trials |
A COA or product page that treats the two as interchangeable is telling you something about the supplier, not the science. Our earlier profile covers the beta side of the family in TB-500 peptide research.
The clinical side of thymosin alpha-1 peptide research spans chronic hepatitis B and C, sepsis, cancer immunotherapy adjuncts, vaccine-response settings, and severe viral infection. Read indication by indication, the record is genuinely mixed — and the largest trials are the least encouraging.
Thymalfasin’s approvals in more than 30 countries rest largely on chronic hepatitis B, where older randomized trials and meta-analyses reported improved response rates, often delayed — responses continuing to rise after treatment ended, consistent with an immune-mediated mechanism. The individual trials were small, however; one frequently cited 1999 randomized study, for example, reported a complete response in 14% of treated patients versus 4% on placebo, a difference that did not reach statistical significance (p = 0.084). In hepatitis C, a large 2012 trial adding Tα1 to peginterferon/ribavirin in 552 previous non-responders found sustained virological response of 12.7% versus 10.5% in controls (p = 0.407) — no significant added benefit.
Sepsis became the flagship modern indication because its late phase involves immune exhaustion that a T-cell-supporting peptide might reverse. The multicenter ETASS trial (Wu and colleagues, Critical Care 2013; 361 patients with severe sepsis) reported 28-day all-cause mortality of 26.0% with Tα1 versus 35.0% in controls — a relative risk of 0.74 that narrowly missed significance on the primary comparison (p = 0.062), with in-hospital mortality significantly lower. Meta-analyses pooling smaller trials suggested a mortality benefit.
The TESTS trial changed the weight of that evidence. Published in The BMJ in 2025, TESTS was a double-blind, placebo-controlled Phase 3 trial enrolling 1,106 adults with sepsis across 22 centers in China. Twenty-eight-day all-cause mortality was 23.4% with thymosin alpha-1 versus 24.1% with placebo (hazard ratio 0.99, 95% CI 0.77–1.27; p = 0.93), and 90-day mortality likewise did not differ. Subgroup analyses hinted at possible benefit in some patients with chronic conditions, but subgroups generate hypotheses — they do not rescue a negative primary endpoint. A 2025 meta-analysis of the sepsis literature fits the same pattern: a signal in the pooled data that disappeared in the higher-quality and multicenter subgroups.
During the pandemic, a retrospective study of 76 patients with severe COVID-19 (Liu and colleagues, Clinical Infectious Diseases) associated Tα1 treatment with lower mortality and restored lymphocyte counts. Retrospective designs cannot exclude confounding, and a 2023 systematic review pooling nine studies and 5,352 patients found a pooled mortality relative risk of about 1.03 with very high heterogeneity — no clear overall benefit. Tα1 has also been explored as a vaccine adjuvant in older adults and as an adjunct in oncology settings such as melanoma and hepatocellular carcinoma, where it received US orphan drug designations for several indications; adjunct and single-arm data in these areas remain preliminary rather than confirmatory.
None of these pharmaceutical registrations changes the status of material supplied strictly for laboratory research. For how that category works, see Understanding Research Use Only (RUO). Researchers sourcing a thymosin alpha-1 research peptide should treat the foreign drug approvals as context for the compound’s history — not as a quality guarantee for any given research lot.
For bench-level thymosin alpha-1 peptide research, identity and purity verification carry unusual weight, because the difference between the correct molecule and a close synthesis error can be a single acetyl group:
Apex’s testing standards, including third-party HPLC and mass-spec verification, are described on our COA & third-party testing page.
No. Thymalfasin (Zadaxin), the pharmaceutical form of the same peptide, is approved in more than 30 other countries, mainly for chronic hepatitis B, but the FDA has approved no product containing thymosin alpha-1, and the EMA has not centrally authorized it either.
No. The Phase 3 TESTS trial (The BMJ, 2025; 1,106 patients) found 28-day mortality of 23.4% on thymosin alpha-1 versus 24.1% on placebo — no significant difference — despite earlier smaller trials such as ETASS suggesting a possible benefit.
No. Tα1 is a 28-amino-acid alpha-thymosin that modulates dendritic cells and T cells. TB-500 is a fragment of thymosin beta-4, a 43-amino-acid actin-binding protein from a different thymosin family, studied in migration and repair models.
Because its dendritic-cell effects run both ways: TLR9/MyD88 signaling supports Th1-type effector responses, while induction of IDO and IL-10 supports tolerance. Which dominates appears to depend on the immune context — one reason simple “immune booster” descriptions misrepresent the research.
HPLC purity with a readable chromatogram, a mass-spectrometry identity match at ~3,108.3 Da confirming the acetylated sequence, the salt form, net peptide content, and a lot number matching the vial.
Related in the Apex shop: Thymosin Alpha-1 research peptide — supplied strictly for laboratory research use.
Research Use Only disclaimer: Thymosin alpha-1 and all products referenced here are supplied strictly for laboratory research use only. They are not intended for human or veterinary use, consumption, diagnostic, or therapeutic purposes, and nothing in this article is medical advice or a claim of safety or efficacy in humans. References to pharmaceutical products and clinical trials in other jurisdictions are provided as research context only. Researchers are responsible for complying with all applicable laws, institutional policies, and laboratory safety requirements.
Selank peptide research starts with an unusual origin story. Most research peptides begin as fragments of a hormone or growth
Retatrutide Peptide Research: The Triple Agonist, TRIUMPH Trials and FDA Status Retatrutide peptide research is where incretin science stopped adding
Sermorelin Peptide Research: GHRH(1-29), GH Pulses and FDA History Sermorelin peptide research occupies an unusual place in the peptide literature:
